FibroGen, Inc.

Equities

FGEN

US31572Q8087

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:43:43 2024-03-28 am EDT 5-day change 1st Jan Change
2.525 USD -2.13% Intraday chart for FibroGen, Inc. +9.32% +191.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
FibroGen Shares Jump After CEO Stock Purchase MT
FibroGen Names Deyaa Adib Chief Medical Officer MT
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer CI
Transcript : FibroGen, Inc., Q4 2023 Earnings Call, Feb 26, 2024
FibroGen regains rights to anemia drug from AstraZeneca RE
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (FGEN) FIBROGEN Reports Q4 Revenue $27.1M, vs. Street Est of $38.8M MT
FibroGen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea CI
Transcript : FibroGen, Inc. - Special Call
FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network?s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from NASDAQ Biotechnology Index CI
Transcript : FibroGen, Inc., Q3 2023 Earnings Call, Nov 06, 2023
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (FGEN) FIBROGEN Reports Q3 Revenue $40.1M, vs. Street Est of $36.8M MT
FibroGen Names Interim Chief Executive Thane Wettig as CEO MT
FibroGen, Inc. Appoints Thane Wettig as a Member of the Board CI
FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from S&P Biotechnology Select Industry Index CI
Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023 CI
Analyst recommendations: Hewlett Packard, Apple, Tesla, Mosaic, Rite Aid... Our Logo
Investors cheer on bad data Our Logo
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Chart FibroGen, Inc.
More charts
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company's product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes. It also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
2.58 USD
Average target price
1.25 USD
Spread / Average Target
-51.55%
Consensus
  1. Stock
  2. Equities
  3. Stock FibroGen, Inc. - Nasdaq
  4. News FibroGen, Inc.
  5. Insider Trends: FibroGen Insider Disposes of Shares for Tax Slowing 90-Day Buy Trend